UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

04 Elevating the lives of people impacted by thymidine kinase 2 deficiency (TK2d)

Read More Share:

Nov

03 U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Read More Share:

Oct

31 Redefining Hidradenitis Suppurativa (HS) Care Through Community and Collaboration

Read More Share:

Oct

31 BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

Read More Share:

Oct

29 UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™

Read More Share:

Oct

29 UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

Read More Share:

Oct

27 Generalized myasthenia gravis management with shared decision-making

Read More Share:

Oct

25 BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis

Read More Share:

Oct

23 Multidisciplinary Collaboration as the Future of Patient-Centered Care

Read More Share:

Oct

14 Innovative Collaborations: Enhancing Epilepsy Care through UCB and Morehouse's Community-Based Approach

Read More Share:

Categories

Archives

Nov

04

Elevating the lives of people impacted by thymidine kinase 2 deficiency (TK2d)

Nov

03

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Oct

31

Redefining Hidradenitis Suppurativa (HS) Care Through Community and Collaboration

Oct

31

BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

Oct

29

UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™

Oct

29

UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

Oct

27

Generalized myasthenia gravis management with shared decision-making

Oct

25

BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis

Oct

23

Multidisciplinary Collaboration as the Future of Patient-Centered Care

Oct

14

Innovative Collaborations: Enhancing Epilepsy Care through UCB and Morehouse's Community-Based Approach

Choose Country

UCB in the U.S.

Patients

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Nov

04

Elevating the lives of people impacted by thymidine kinase 2 deficiency (TK2d)

Nov

03

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Oct

31

Redefining Hidradenitis Suppurativa (HS) Care Through Community and Collaboration

Oct

31

BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

Oct

29

UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™

Oct

29

UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

Oct

27

Generalized myasthenia gravis management with shared decision-making

Oct

25

BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis

Oct

23

Multidisciplinary Collaboration as the Future of Patient-Centered Care

Oct

14

Innovative Collaborations: Enhancing Epilepsy Care through UCB and Morehouse's Community-Based Approach

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Disease Areas

Sustainability

Newsroom

Contact